Head of U.S. clinical development program is David Richards, MD, who holds the title of senior VP-medical operations. Richards assumed that position last fall moving over from Glaxo Group Research, where he was a medical director. "The Pink Sheet" previously reported incorrectly that Peter Wise, MD, is head of the Glaxo, a medical director. "The Pink Sheet" previously reported incorrectly that Peter Wise, MD, is head of the Glaxo, Inc. clinical programs. Wise holds the title of senior VP-medical marketing and heads a research group that develops new uses for already marketed products as well as line extensions, dosage regimens, and new market niches.
You may also be interested in...
The UK medicines regulator has a “unique opportunity” to evaluate the systems it operates and to “do things differently", according to its long-term interim head, June Raine.
No device-related warning letters were released by the US FDA the week of 22 September.
Created in 2016 by consolidating five European companies, CNS specialist Neuraxpharm is changing hands, with funds advised by global investor Permira paying an undisclosed sum to take control of a business boasting annual revenues of around €460m ($541m) and more than 115 CNS molecules at its disposal.